Archive | SIRION Biotech GmbH

Page 5 of 6
SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study
SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study Learn More >
SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16
SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16 Learn More >
SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume
SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume Learn More >
45154Customized adenoviral vectors (AVs)
Customized adenoviral vectors (AVs) Learn More >
SIRION Biotech expands business and ideas
SIRION Biotech expands business and ideas Learn More >
SIRION Biotech announces preclinical vaccination success
SIRION Biotech announces preclinical vaccination success Learn More >
Modifying iPS Cells With Lentivirus to build more robust disease models
Modifying iPS Cells With Lentivirus to build more robust disease models Learn More >
45142ProVector™: Protecting production cells from problematic transgene expression
ProVector™: Protecting production cells from problematic transgene expression Learn More >
SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe
SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe Learn More >
SIRION Biotech bringing latest viral vector insights to ELRIG Drug Discovery ’15
SIRION Biotech bringing latest viral vector insights to ELRIG Drug Discovery ’15 Learn More >
Viral vector specialist SIRION Biotech heading to ECC2015 Vienna
Viral vector specialist SIRION Biotech heading to ECC2015 Vienna Learn More >
Research confirms superiority of SIRION Biotech’s AAV vectors and Lentivirus strategies
Research confirms superiority of SIRION Biotech’s AAV vectors and Lentivirus strategies Learn More >
Page 5 of 6